13 , 15 Similarly in our work, there was an overall trend of reclassification from a higher risk category to a lower risk category, which would affect statin eligibility in 19% of this population who were previously statin-eligible according the most recent ACC/AHA primary prevention guidelines using PCE risk stratification. 16 Our analysis suggests that reclassification was generally appropriate with only 83 (3.2%) people who were reclassified from a higher risk to lower risk category went on to have an ASCVD event.
1
—
—